Compare · CPRX vs NVO
CPRX vs NVO
Side-by-side comparison of Catalyst Pharmaceuticals Inc. (CPRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CPRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 57.8x CPRX ($3.85B).
- CPRX has been more active in the news (42 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 7 for CPRX).
- Company
- Catalyst Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $3.85B
- $222.81B
- 1M return
- +0.41%
- -
- 1Y return
- +49.63%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 42
- 5
- Recent ratings
- 7
- 25
Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CPRX
- Chief HR Officer Russo Gregg returned $14,994 worth of shares to the company (476 units at $31.50), closing all direct ownership in the company (SEC Form 4) (withholding tax)
- Chief Legal Officer Elsbernd Brian returned $7,638,782 worth of shares to the company (242,501 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- SEC Form 4 filed by Director Curran Daniel J. to cover taxes
- Director Thompson Tamar returned $118,850 worth of shares to the company (3,773 units at $31.50), closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax
- Chief Op. & Scientific Officer Miller Steve returned $34,454,794 worth of shares to the company (1,093,803 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax withholding)
- Director Tierney David S returned $12,074,391 worth of shares to the company (383,314 units at $31.50), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Strategy Officer Sundaram Preethi returned $1,726,326 worth of shares to the company (54,804 units at $31.50), closing all direct ownership in the company (SEC Form 4) to cover withholding tax
- Chairman of Board of Directors Mcenany Patrick J returned $131,404,108 worth of shares to the company (4,171,559 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President and CEO Daly Richard J returned $8,544,879 worth of shares to the company (271,266 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Del Carmen Jeffrey returned $451,616 worth of shares to the company (14,337 units at $31.50), closing all direct ownership in the company (SEC Form 4) (for tax liability)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S